Otsuka Holdings
4578.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥98.8bn | ¥118.0bn | ¥82.4bn | ¥57.0bn | ¥115.0bn | ¥102.7bn |
| Operating income | ¥82.7bn | ¥102.9bn | ¥69.0bn | ¥44.3bn | ¥103.4bn | — |
| Ordinary income | ¥84.2bn | ¥105.0bn | ¥70.0bn | ¥46.4bn | ¥104.8bn | ¥93.5bn |
| Total assets | ¥1.32T | ¥1.38T | ¥1.21T | ¥1.27T | ¥1.25T | ¥1.21T |
| Net assets / equity | ¥1.03T | ¥1.07T | ¥1.08T | ¥1.06T | ¥1.07T | ¥1.02T |
| EPS (basic) | ¥169.52 | ¥196.52 | ¥130.92 | ¥87.37 | ¥195.5 | ¥174.03 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 81 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Consumer Products | ¥34.6bn | ¥25.1bn |
| Nutraceuticals | ¥577.6bn | ¥57.7bn |
| Other | ¥112.4bn | ¥8.0bn |
| Pharmaceuticals | ¥1.74T | ¥445.3bn |
| Adjustments & eliminations | — | −¥56.8bn |
| Total | ¥2.47T | ¥536.2bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.